Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.
BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comme...
BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...
BioNTech SE ( NASDAQ:BNTX ) just released its latest annual report and things are not looking great. BioNTech missed...
BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript March 20, 2024 BioNTech SE misses on earnings expectations. Reported EPS is $1.9 EPS, expectations were $2.64. BNTX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the BioNTech’s Fourth Quarter […]
Q4 2023 BioNTech SE Earnings Call
BioNTech stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit.
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. On Wednesday, BioNTech reported a revenue and earnings drop as it continues its shift towards cancer drug development, much like its peer Pfizer who also turned to oncology in response to falling sales. In January, Pfizer revealed that sales of the COVID shot plummeted 54% to $5.36 billion. Upon its latest repo
BNTX earnings call for the period ending December 31, 2023.
BioNTech estimates that its 10 most advanced cancer treatment candidates could generate combined peak sales of more than 10 billion euros ($10.9 billion), after reporting an ongoing decline in its COVID-19 vaccine business. "The peak sales estimate for that collection of assets is actually well over 10 billion euros in our long term estimates," BioNTech's head of strategy, Ryan Richardson, said in analyst call on Wednesday after the release of 2023 results. He would not be drawn on a combined ...